spacer
home > pmps > spring 2007 > innovation in a bigger box
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Innovation in a Bigger Box

If healthcare companies are not as innovative as their shareholders would like, it’s not for want of trying – or even due to a lack of good ideas. PA Consulting Group’s Paul Earnshaw argues that by stretching the boundaries of your own ‘innovation box’ you can maximise chances of success

Most pharmaceutical and medical device companies have recognised innovation as a primary driver of profit and growth. Many of them are successful at generating ideas, and even at identifying those with the greatest potential – at least in theory. What defeats companies time and time again is managing new drugs or devices through to a successful launch, especially if they take the company in question outside its core comfort zone.

Companies need to find a way to take full and accurate account of the real-world – of the ‘innovation box’ in which they are operating. Ideas that work well on paper can fail when they come up against real-world constraints, such as capital cost, requirements for consistent quality and the need to secure regulatory approval.

The value of taking a real-world perspective is not only that it makes you aware of constraints; it can also liberate your creativity and enlarge your company’s innovation box. Pharmaceutical and medical device companies typically have a pessimistic idea of what is technically viable, and are too ready to discard ideas that strike them as ‘off the wall’. However, what is ‘off the wall’ to one company may be far less extraordinary to those from another sector.

By looking harder at the realworld context, and understanding constraints at a more fundamental level, companies may discover that some of their wackier ideas are actually viable. They may also be faster and less costly to deliver than others that on the surface are front runners and fall within the organisation’s comfort zone. So, how can you gauge the true limits of the innovation box in which you’re operating, so as to spot the healthcare ideas that can win in the real-world and maximise chances of success?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Paul Earnshaw has a background in the development, specification and sourcing of new packaging and manufacturing processes. He is a Packaging and Materials Engineer with significant experience of implementing novel products across all areas of consumer products – ranging from the development of new delivery formats for pharmaceutical and dental products, through to innovative materials processing systems for food. Paul’s work on projects of this type has given him an in-depth understanding of how to translate consumer requirements into robust, cost-conscious engineering solutions which can be readily industrialised.
spacer
Paul Earnshaw
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

Role of Comparators in Clinical Trial Supply

Clinical Services International

CSI analyses the role of comparators in different trial designs and offers expert advice on robust methodology for choosing the most appropriate comparators. Case studies provide real insight on how to choose comparators for rare diseases and oncology studies.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement